Tim McCarthy updates on Phase III study – 17th May 2017

Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) tells Proactive they’re on schedule to publish first results from their phase III trial of lupus drug Lupuzor early next year with all 200 patients now having had at least three months worth of treatment.